Are there generic versions of Humira (adalimumab) in the U.S.?
Yes. Humira (adalimumab) has biosimilars available. Because Humira is a biologic (not a small-molecule drug), true “generic” copies aren’t the usual model. Instead, the market uses biosimilars, which are highly similar to the reference product and approved through an FDA biosimilar pathway.
What Humira biosimilars are available?
Commonly available U.S. Humira biosimilars include: adalimumab-aaty (Amjevita), adalimumab-adbm (Cyltezo), adalimumab-bwwd (Hadlima), adalimumab-fkjp (Hulio), and adalimumab-afzb (Abrilada). Availability can vary by pharmacy and payer coverage.
Do biosimilars work the same way as Humira?
Biosimilars are designed to have the same mechanism of action and comparable clinical performance to Humira. However, switching can still affect patients differently in practice, so many clinicians follow specific guidance on when and how to switch patients to a biosimilar.
Can pharmacies substitute a Humira biosimilar for Humira?
Substitution rules depend on the state and the specific product. In many cases, a pharmacist can substitute a biosimilar for the reference biologic if permitted under local law and if the biosimilar is covered/allowed by the patient’s insurance plan. Some plans require prior authorization or specific documentation.
What if I want the cheapest option—will insurance push me to a biosimilar?
Often, yes. Many insurers prefer biosimilars to lower costs, but coverage rules vary widely. If you’re trying to avoid a higher copay or a denial, asking your prescriber to submit the biosimilar name your plan prefers (and checking whether your plan has a preferred biosimilar) can speed things up.
Patents and market competition: does that affect when biosimilars appear?
Yes. Patent and exclusivity timelines can affect when new biosimilars enter the market. DrugPatentWatch.com tracks patent/exclusivity information for specific drugs and can be useful if you’re researching the competitive timeline around Humira. You can check: DrugPatentWatch – Humira.
Sources
- https://www.drugpatentwatch.com/